A Multicenter, Randomized, Double-Blind, Placebo-Controlled, and Dose-Increasing Study on the Safety, Tolerability and PK/PD of Multiple Doses of HSK7653 by Oral Administration in Patients with Type 2 Diabetes Mellitus in China

IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045

(2021) Hong Sun et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Design, Synthesis and Evaluation of a Series of Novel Super-long Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes

(2020) Chen Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Genetics of diabetes mellitus and diabetes complications

(2020) Joanne B. Cole et al.   Nature Reviews Nephrology

The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes

(2020) Anca Pantea Stoian et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

(2020) Carolyn F. Deacon   Nature Reviews Endocrinology

Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000–2018

(2019) Sara Ramzan et al.   Primary Care Diabetes

Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and α-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials

(2019) Zhaoliang Li et al.   Frontiers in Pharmacology

QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study)

(2019) Suhas Erande et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?

(2017) Kashif M. Munir et al.   EXPERT OPINION ON PHARMACOTHERAPY

Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip

(2017) Michaela Luconi et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor

(2016) David W. Boulton   CLINICAL PHARMACOKINETICS

Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas

(2016) C. F. Deacon et al.   DIABETES OBESITY & METABOLISM

Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality

(2016) Jan W. Eriksson et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

(2016) Charles E. Grimshaw et al.   PLoS One

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes

(2015) Wayne H.-H. Sheu et al.   DIABETES CARE

Once-weekly DPP-4 inhibitors: do they meet an unmet need?

(2015) André J Scheen   Lancet Diabetes & Endocrinology

DPP-4 inhibitors: focus on safety

(2014) Sri Harsha Tella et al.   Expert Opinion On Drug Safety

Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison

(2014) Paul Craddy et al.   Diabetes Therapy

The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses

(2011) Arne Ring et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes

(2011) Carl Asche et al.   CLINICAL THERAPEUTICS

A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects

(2009) Daniel M. Bloomfield et al.   JOURNAL OF CLINICAL PHARMACOLOGY